Elpis Biopharmaceuticals Enters Collaboration with Singapore General Hospital
The exciting partnership between Elpis Biopharmaceuticals and Singapore General Hospital (SGH) is set to drive advancements in innovative cancer therapies. This collaboration focuses on the development of next-generation allogeneic CAR (Chimeric Antigen Receptor) technologies, specifically targeting acute myeloid leukemia (AML) and multiple myeloma (MM). As a clinical-stage cell therapy company, Elpis is dedicated to creating bispecific armored CAR-T therapies for solid tumors.
The Nature of the Research Collaboration
Under their agreement, Elpis will share their advanced bispecific and armored CAR technologies with SGH through a successful technology transfer completed in late April. SGH plans to utilize its unique ??T platform and extensive clinical expertise to propel the development of these targeted cancer therapies into investigator-initiated trials. If the resulting data proves beneficial, both organizations intend to explore forming a joint venture for further development and commercialization of these promising therapies.
Advancements in Cancer Therapy
Elpis Biopharmaceuticals is on the cutting edge of cancer treatment, specifically through their CAR-??T technology, which has the potential to revolutionize how we approach immune therapies. According to Assistant Professor Alice Cheung, a Junior Principal Investigator at SGH, CAR-??Ts wield the ability to harness the immune system comprehensively, positioning them as a formidable tool in cancer treatment.
Goals of the Research Initiative
Assistant Professor Chen Yunxin, a Senior Consultant at SGH, emphasized their goal of developing powerful and enduring cell therapies for AML and MM. By incorporating robust immune modulation, the partnership aspires to enhance the antitumor effects and improve patient outcomes significantly.
Innovations Backed by Advanced Technology
Elpis has been relentlessly working on a suite of proprietary technologies designed to tackle key challenges in tumor treatment effectively. These challenges include the suppression of immune response within the tumor microenvironment (TME) and variability in antigens among tumors. The precision-engineered immune cell armor is intended to enhance the persistence of CAR-engineered immune cells and improve bystander immune cell activities.
Commitment to Next-Generation CAR Technologies
Yan Chen, MD, PhD, the founder and CEO of Elpis Biopharmaceuticals, articulated the company's commitment to elevating CAR-??Ts to the next level by integrating cell type-specific multi-mechanism armor with bi-specific tumor-targeting antibodies. These technological advancements are envisioned to overcome various resistance mechanisms, offering safer, more effective, and longer-lasting therapies at a significantly reduced cost compared to traditional autologous CAR-T therapies. Elpis is enthusiastic about its collaboration with SGH as they embark on pivotal clinical trials aimed at tackling AML and multiple myeloma.
About Elpis Biopharmaceuticals
Elpis Biopharmaceuticals stands as a trailblazer in the realm of clinical-stage biopharmaceuticals, focusing on next-generation cell therapies targeted at solid tumors. The company is committed to developing a robust pipeline of cutting-edge bispecific armored CAR-T therapies that address critical obstacles such as tumor heterogeneity and the immunosuppressive TME. Their proprietary technologies encompass multi-mechanism armor, bispecific targeting antibodies, a specialized cytokine cocktail manufacturing process, and a rapid mRNA discovery platform, all aimed at ensuring patients receive safer and more durable therapeutic responses. With leading programs addressing conditions like glioblastoma and various solid tumors, Elpis Biopharmaceuticals continues to innovate from its headquarters.
About Singapore General Hospital
As Singapore's largest tertiary hospital, established in 1821, SGH is a cornerstone of healthcare in the region. It is renowned for providing comprehensive patient-centered care across more than 50 clinical specialties. As an Academic Medical Centre, SGH is dedicated to training future healthcare professionals and spearheading research to meet the evolving health needs of the nation and beyond. SGH prides itself on its commitment to excellence in patient care and research, maintaining a profound sense of trust and hope within the community.
Frequently Asked Questions
What is the focus of the collaboration between Elpis Biopharmaceuticals and SGH?
The collaboration aims to develop next-generation allogeneic CAR technologies targeting AML and MM.
What technologies will Elpis Biopharmaceuticals provide to SGH?
Elpis will contribute its bispecific and armored CAR technologies to SGH as part of the technology transfer.
What are the expected outcomes of this collaboration?
This collaboration aims to enhance the development of cell therapies, which could lead to improved clinical outcomes for cancer patients.
Who are the key scientists involved in this collaboration?
Assistant Professors Alice Cheung and Chen Yunxin from SGH are leading the research efforts in this collaboration.
Where is Elpis Biopharmaceuticals headquartered?
Elpis Biopharmaceuticals operates its headquarters in Lexington, MA, as well as in Singapore.
